Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000689012 | SCV000816647 | uncertain significance | Charcot-Marie-Tooth disease dominant intermediate B | 2018-01-01 | criteria provided, single submitter | clinical testing | This sequence change removes the last 8 nucleotides of exon 8 and the first nucleotide of intron 9, affecting a donor splice site in intron 9 of the DNM2 gene. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this change results in two abnormally spliced mRNA transcripts from the DNM2 gene, resulting in a protein with a premature truncation, p.Asp555Valfs*35 (also known as K550fs), or an in-frame deletion, p.Asp555_Glu557del (PMID: 15731758). p.Asp555_Glu557del is also known as 555delta3 or D551_E553del in the literature. Lysates from affected individuals with this variant did not show a reduced level of protein, suggesting that nonsense-mediated decay was not activated (PMID: 15731758). However, experiments show that protein containing p.Asp555_Glu557del is defective in microtubule organization, formation and endocytosis (PMID: 15731758, 21762456, 27328317). This variant has been reported in an individual affected with Charcot-Marie-Tooth disease (PMID: 15731758). This variant is not present in population databases (ExAC no frequency). |
OMIM | RCV000689012 | SCV000027900 | pathogenic | Charcot-Marie-Tooth disease dominant intermediate B | 2005-03-01 | no assertion criteria provided | literature only | |
Inherited Neuropathy Consortium | RCV000789091 | SCV000928442 | uncertain significance | Charcot-Marie-Tooth disease | no assertion criteria provided | literature only | ||
Inherited Neuropathy Consortium Ii, |
RCV000689012 | SCV004174770 | uncertain significance | Charcot-Marie-Tooth disease dominant intermediate B | 2016-01-06 | no assertion criteria provided | literature only |